All In Biotech

Drug Trial Radar · NCT03834753

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

228

Actual

Start

Jun 25, 2019

Primary completion

Jun 7, 2021

Study completion Jul 8, 2021

Sponsor

Lead sponsor
Outlook Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

Conditions

  • Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Wet Macular Degeneration

Interventions

  • bevacizumabBiological

    1.25 mg, intravitreal injection

  • ranibizumabBiological

    0.5mg, intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)Time frame: 11 months

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Tucson, Arizona

  • Clinical Site

    Arcadia, California

  • Clinical Site

    Beverly Hills, California

  • Clinical Site

    Campbell, California

  • Clinical Site

    Glendale, California

  • Clinical Site

    Laguna Hills, California

  • Clinical Site

    Long Beach, California

  • Clinical Site

    Mountain View, California

  • Clinical Site

    Oxnard, California

  • Clinical Site

    Palm Desert, California

  • Clinical Site

    Poway, California

  • Clinical Site

    Sacramento, California

  • Clinical Site

    Santa Maria, California

  • Clinical Site

    Tustin, California

  • Clinical Site

    Golden, Colorado

  • Clinical Site

    Hamden, Connecticut

  • Clinical Site

    Clearwater, Florida

  • Clinical Site

    Pinellas Park, Florida

  • Clinical Site

    Sarasota, Florida

  • Clinical Site

    Winter Haven, Florida

  • Clinical Site

    Augusta, Georgia

  • Clinical Site

    Marietta, Georgia

  • Clinical Site

    Downers Grove, Illinois

  • Clinical Site

    Lemont, Illinois

  • Clinical Site

    Springfield, Illinois

  • Clinical Site

    Indianapolis, Indiana

  • Clinical Site

    Hagerstown, Maryland

  • Clinical Site

    Edina, Minnesota

  • Clinical Site

    St Louis, Missouri

  • Clinical Site

    Bloomfield, New Jersey

  • Clinical Site

    Albuquerque, New Mexico

  • Clinical Site

    New York, New York

  • Clinical Site

    Chambersburg, Pennsylvania

  • Clinical Site

    Monroeville, Pennsylvania

  • Clinical Site

    Rapid City, South Dakota

  • Clinical Site

    Germantown, Tennessee

  • Clinical Site

    Abilene, Texas

  • Clinical Site

    Amarillo, Texas

  • Clinical Site

    Arlington, Texas

  • Clinical Site

    Dallas, Texas

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.